PRINCETON, N.J., Dec. 5 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that the live webcast of presentations highlighting current and future programs at the Medarex 2005 R&D Day is scheduled to begin at 8:00 AM ET and end at approximately 12:30 PM ET on Friday, December 9, 2005. In addition to presentations by Medarex senior management, invited guest speakers include Donna M. Ambrosino, M.D., Director of Massachusetts Biologic Laboratories and Professor of Pediatrics at the University of Massachusetts Medical School; and Jeffrey S. Weber, M.D., Ph.D., Chief of Oncology at the Keck School of Medicine of the University of Southern California.
The live webcast and archive will be made available on the Webcasts page in the Investor Relations section of the Medarex website via the Internet at www.medarex.com/Investor/Webcasts.htm and will be archived for at least three months.
For further information on the Medarex 2005 R&D Day, please contact Dawn Wolfe at 609-436-8909 or by email at RD2005@medarex.com.
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Twenty-six of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with two of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
Medarex, Inc.CONTACT: Laura S. Choi, Investor Relations, +1-609-430-2880, x2216, orJean Mantuano, Corporate Communications (media), +1-609-430-2880, x2221,both of Medarex
Web site: http://www.medarex.com/
Company News On-Call: http://www.prnewswire.com/comp/108265.html/
